Fulvestrant

Generic Name
Fulvestrant
Brand Names
Faslodex, Fulvestrant Mylan
Drug Type
Small Molecule
Chemical Formula
C32H47F5O3S
CAS Number
129453-61-8
Unique Ingredient Identifier
22X328QOC4
Background

Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...

Indication

For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.

Associated Conditions
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Associated Therapies
-

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2015-01-16
Last Posted Date
2022-07-12
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
631
Registration Number
NCT02340221
Locations
🇦🇹

Lkh-Univ. Klinikum Graz; Klinik Für Innere Medizin I, Graz, Austria

🇦🇹

Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria

🇧🇬

Complex Oncological Center - Plovdiv, EOOD, Plovdiv, Bulgaria

and more 154 locations

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

First Posted Date
2014-11-17
Last Posted Date
2020-02-17
Lead Sponsor
SCRI Development Innovations, LLC
Target Recruit Count
48
Registration Number
NCT02291913
Locations
🇺🇸

Woodlands Medical Specialists, Pensacola, Florida, United States

🇺🇸

Hope Cancer Center, Terre Haute, Indiana, United States

🇺🇸

Center for Cancer and Blood Disorders, Fort Worth, Texas, United States

and more 5 locations

Phase II Study of Everolimus Beyond Progression

First Posted Date
2014-10-21
Last Posted Date
2022-04-05
Lead Sponsor
Emory University
Target Recruit Count
3
Registration Number
NCT02269670
Locations
🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

First Posted Date
2014-08-15
Last Posted Date
2024-12-02
Lead Sponsor
Queen Mary University of London
Target Recruit Count
333
Registration Number
NCT02216786
Locations
🇬🇪

Tbilisi Cancer Center, Tbilisi, Georgia

🇵🇹

Ipo Porto, Porto, Portugal

🇭🇺

Bacs-Kiskun County Hospital, Kalocsa, Hungary

and more 76 locations

Endocrine Response in Women With Invasive Lobular Breast Cancer

First Posted Date
2014-08-01
Last Posted Date
2024-08-22
Lead Sponsor
Priscilla McAuliffe
Target Recruit Count
201
Registration Number
NCT02206984
Locations
🇺🇸

Univ. of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

🇺🇸

ALBERT EINSTEIN COLLEGE OF MEDICINE Montefiore Medical Center, Bronx, New York, United States

🇺🇸

Josh Plassmeyer, Pittsburgh, Pennsylvania, United States

and more 9 locations

Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC

First Posted Date
2014-05-16
Last Posted Date
2015-12-29
Lead Sponsor
Fudan University
Registration Number
NCT02140437

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

First Posted Date
2014-05-14
Last Posted Date
2021-01-28
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
37
Registration Number
NCT02137837
Locations
🇺🇸

St. Patrick Hospital, Missoula, Montana, United States

🇺🇸

Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States

🇺🇸

Clackamas Radiation Oncology Center, Clackamas, Oregon, United States

and more 220 locations

A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2014-05-13
Last Posted Date
2018-01-23
Lead Sponsor
Fudan University
Target Recruit Count
22
Registration Number
NCT02137083
Locations
🇨🇳

Fudan University Cancer Hospital, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath